Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²)
NCT04320420 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57
Last updated 2021-10-08
Summary
Therapeutic intensification followed by an autograft of hematopoietic stem cells is a standard of care for young patients with myeloma from the first line and for lymphoma from the second or third line of treatment. This procedure remains toxic in the short and medium term with significant mortality and morbidity: the average mortality varies from 1.4 to 5%. The causes of death are linked to a severe infection, visceral bleeding or vital organ failure. This risk of mortality is partly correlated with sarcopenia.
Sarcopenia is defined by the reduction of muscle mass and strength. It was first described in the elderly and classified as geriatric syndrome such as dementia, falls or frailty. It varies from 5 to 13% between 60 and 70 years and between 11 and 50% beyond 80 years and is classified as primitive, that is to say related to age It can however be secondary to neoplasia. This event has been described in patients with hematologic malignancies during chemotherapy and can reach 55% of patients in the elderly. It is proportional to the intensity of the treatments. It emerges as an independent prognostic factor which is detrimental to survival in these patients. Physical exercise combined with nutritional support could reduce it.
The positive impact of adapted physical activity (APA) has been shown in numerous publications on reducing the incidence and risk of relapse for several cancers (breast, colon prostate). It is less obvious in hematology in view of studies published on APA with different physical activity programs depending on the time of the intervention or according to the type, duration and intensity.
The objective of this study is to assess the feasibility of an APA program in patients requiring an autologous hematopoietic stem cell transplant. It is expected that the program will have a protective effect on the appearance of induced sarcopenia and on the complications related to the procedure in the short and medium term regardless of the hematology center for patients receiving intensive treatment with support for autologous hematopoietic stem cells.
This is a feasibility study.
Conditions
Interventions
- OTHER
-
Adapted Physical Activity
The APA program is defined in 3 stages: STEP 1: during the initial chemotherapy over 3 months * 3 supervised APA sessions/week on site: * two muscle strengthening sessions, stretching, flexibility in the gym * a cardio session (Nordic Walking: outdoors) * at home: exercise book if the patient wishes STEP 2: during hospitalization for the autograft, over 1 month: * 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work * If the patient wishes, he can continue the exercises carried out with the APA engineer independently STEP 3: after the transplant * the first 3 months: * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility), * 1-hour cardio session/week independently * the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions
Sponsors & Collaborators
-
Weprom
lead OTHER
Principal Investigators
-
Katell LE DU, MD · Centre Jean Bernard/Clinique Victor Hugo
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-20
- Primary Completion
- 2023-04-30
- Completion
- 2024-10-31
Countries
- France
Study Locations
More Related Trials
-
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
NCT00060255 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
NCT00615589 ·Status: TERMINATED ·Phase: PHASE2
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
NCT05642884 ·Status: RECRUITING ·Phase: NA
-
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
NCT00244946 ·Status: COMPLETED ·Phase: PHASE1
-
Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
NCT06773871 ·Status: RECRUITING ·Phase: NA
-
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT06520163 ·Status: RECRUITING ·Phase: PHASE3
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
NCT04678427 ·Status: RECRUITING ·Phase: NA
-
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
NCT00002553 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms
NCT04981821 ·Status: RECRUITING ·Phase: NA
-
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
NCT01558778 ·Status: WITHDRAWN ·Phase: NA
-
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
NCT01008462 ·Status: COMPLETED ·Phase: PHASE2
-
High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
NCT00002630 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
NCT05181540 ·Status: TERMINATED ·Phase: PHASE3
-
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
NCT00313625 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma
NCT01969942 ·Status: WITHDRAWN ·Phase: PHASE1
-
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT00024466 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00004899 ·Status: COMPLETED ·Phase: PHASE2
-
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
NCT00002665 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
NCT00027547 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Allogeneic Cell Therapy for Adults With Hematologic Malignancies
NCT00208962 ·Status: COMPLETED ·Phase: PHASE2
-
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
NCT01795430 ·Status: WITHDRAWN ·Phase: NA
-
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
NCT00004907 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
NCT00429507 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
NCT00004905 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
NCT03858205 ·Status: RECRUITING ·Phase: NA